產品詳情
簡單介紹：
Anti-PEA15抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-PEA15抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-PEA15
Cat. Number:
Anti-PEA15抗體KL-3524R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PED/PEA 15 (Phosphoprotein Enriched in Diabetes/Phosphoprotein Enriched in Astrocytes 15 kDa) is a widely expressed 15 kDa protein comprised of an N terminal region containing a canonical Death Effector Domain (DED)Anti-PEA15抗體 sequence and a nuclear export signal, and a C terminal region containing two serine phosphorylation sites. PED/PEA 15 has been implicated in the regulation of multiple cellular processes including apoptosis, integrin activation, and insulin sensitive glucose transport in insulin responsive cells. Phosphorylation of both serine 104 (a Protein Kinase C site) and serine 116 (a substrate of CaMKII and Akt) is required for PED/PEA 15 function.
Also known as:
Astrocytic phosphoprotein PEA 15; Anti-PEA15抗體Astrocytic phosphoprotein PEA15; HMAT 1; HMAT1; Homolog of mouse MAT 1 oncogene; Homolog of mouse MAT1 oncogene; HUMMAT 1H; HUMMAT1H; MAT 1; MAT 1H; MAT1; MAT1H; PEA 15; PEA-15； PEA15 protein; PED; Phosphoprotein enriched in astrocytes 15; Phosphoprotein enriched in astrocytes 15kD; Phosphoprotein enriched in diabetes; PEA15_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity Anti-PEA15抗體purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human PEA15.
●
Predicted Molecular Weight: 15kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-PEA15抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-PEA15抗體
Optimal working dilutions must be determined by the end user.
